← Leaderboards
David Ives
Beth Israel Deaconess Medical Center
$387,832
Attributed
$387,832
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$387,832 · 5
By mechanism
M01$387,832 · 5
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Carmelo Nucera$4,177,998
- Scott Hammer$387,832
- Michael B Atkins$4,622,469
- Daniel Botelho Costa$3,158,732
- Lorraine Kyne$661,148
Others in their field
Top investigators on “Aids Therapy”
- Lawrence Corey · Fred Hutchinson Cancer Center$356,191,804
- Constance Ann Benson · University Of California, San Diego$277,003,036
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$262,875,323
- Barbara Driver · Westat, Inc.$205,980,213
- Sharon A Nachman · Johns Hopkins University$193,704,208
- Carol Nesel · Westat$188,148,170
Research focus
Aids TherapyHuman SubjectClinical ResearchHuman Therapy EvaluationAntiviral AgentsClinical Trial Phase IHiv InfectionsAntiaids AgentNucleoside AnalogCombination ChemotherapyDrug Screening /EvaluationHelper T LymphocyteAzithromycinCombination TherapyDisease /Disorder Prevention /ControlDrug Administration RoutesEnzyme InhibitorsProtease InhibitorRna Directed Dna PolymeraseVirus LoadImmunotherapyInterleukin 2Intravenous AdministrationLeukocyte Count
Grant awards (22)
ACTG 362: EFFICACY OF AZITHROMYCIN PROPHYLAXIS AGAINST MAC DISEASE$0
M01 · FY2002 · RR
ACTG 364--NELFANIVIR AND/OR DMF 266 IN COMBINATION WITH NUCLEOSIDE ANALOG$0
M01 · FY2002 · RR
ACTG 368--IDV, DMP2268, AND 1592U89 IN HIV SUBJECTS$0
M01 · FY2002 · RR
ACTG 328--INTERMITTENT RHIL 2 BY IV OR SQ ADMINISTRATION ON HAART VS HAART ONLY$0
M01 · FY2002 · RR
ACTG 362: EFFICACY OF AZITHROMYCIN PROPHYLAXIS AGAINST MAC DISEASE$0
M01 · FY2001 · RR
ACTG 368--IDV, DMP2268, AND 1592U89 IN HIV SUBJECTS$0
M01 · FY2001 · RR
ACTG 328--INTERMITTENT RHIL 2 BY IV OR SQ ADMINISTRATION ON HAART VS HAART ONLY$0
M01 · FY2001 · RR
ACTG 364--NELFANIVIR AND/OR DMF 266 IN COMBINATION WITH NUCLEOSIDE ANALOG$0
M01 · FY2001 · RR
ACTG 360: OBSERVATIONAL STUDY OF CMV &HIV VIRAL BURDEN$193,916
M01 · FY2000 · RR
ACTG 360: OBSERVATIONAL STUDY OF CMV &HIV VIRAL BURDEN$193,916
M01 · FY2000 · RR
ACTG 362: EFFICACY OF AZITHROMYCIN PROPHYLAXIS AGAINST MAC DISEASE$0
M01 · FY2000 · RR
ACTG 362: EFFICACY OF AZITHROMYCIN PROPHYLAXIS AGAINST MAC DISEASE$0
M01 · FY2000 · RR
ACTG 362: EFFICACY OF AZITHROMYCIN PROPHYLAXIS AGAINST MAC DISEASE$0
M01 · FY2000 · RR
ACTG 368--IDV, DMP2268, AND 1592U89 IN HIV SUBJECTS$0
M01 · FY2000 · RR
ACTG 368--IDV, DMP2268, AND 1592U89 IN HIV SUBJECTS$0
M01 · FY2000 · RR
ACTG 328--INTERMITTENT RHIL 2 BY IV OR SQ ADMINISTRATION ON HAART VS HAART ONLY$0
M01 · FY2000 · RR
ACTG 328--INTERMITTENT RHIL 2 BY IV OR SQ ADMINISTRATION ON HAART VS HAART ONLY$0
M01 · FY2000 · RR
ACTG 328--INTERMITTENT RHIL 2 BY IV OR SQ ADMINISTRATION ON HAART VS HAART ONLY$0
M01 · FY2000 · RR
ACTG 364--NELFANIVIR AND/OR DMF 266 IN COMBINATION WITH NUCLEOSIDE ANALOG$0
M01 · FY2000 · RR
ACTG 364--NELFANIVIR AND/OR DMF 266 IN COMBINATION WITH NUCLEOSIDE ANALOG$0
M01 · FY2000 · RR
ACTG 364--NELFANIVIR AND/OR DMF 266 IN COMBINATION WITH NUCLEOSIDE ANALOG$0
M01 · FY2000 · RR
ACTG 368--IDV, DMP2268, AND 1592U89 IN HIV SUBJECTS$0
M01 · FY2000 · RR